Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

40.13 -0.57 (-1.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Via TheNewswire.com
Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗
Via Chartmill
News headline image
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
News headline image
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox &amp; Kilsheimer LLP Regarding Potential Securities Law Violations
Via TheNewswire.com
News headline image
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations
Via TheNewswire.com
Topics Fraud
News headline image
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing
From Hagens Berman
Via Business Wire
News headline image
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations
Via TheNewswire.com
News headline image
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say ↗
As per the letter published by the FDA, the agency had alerted the company regarding its concerns for Relacorilant before. 
Via Stocktwits
News headline image
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
From Bernstein Liebhard LLP
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
News headline image
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
2 Stocks Under $50 to Target This Week and 1 We Turn Down
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.